Aldehyde-Functionalized Magnetic Particles to Capture Off-Target Chemotherapeutic Agents by Krishnamoorthy, Sankarganesh & Grubbs, Robert H.
	 S1	
Aldehyde-Functionalized Magnetic Particles to Capture Off-target 
Chemotherapeutic Agents  
Sankarganesh Krishnamoorthy and Robert H. Grubbs* 
 
Division of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, California 
91125, United States  
 
 
rhg@caltech.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 S2	
Table of contents  
1. Imine formation in D2O (1H NMR; Figure S1) 
2. Preparation of IONP-VB6,  
3. DOX capture (UV-Vis; Figure S2) from PBS using IONP-VB6 (Table S1),  
4. DOX capture from human serum IONP-VB6-RT (emission spectrum; Figure S3),  
5. Release of DOX in aq. Acid from IONP-VB6 (Figure S4),  
6. Preparation of IONP-3,4-dihydroxybenzaldehyde and DOX capture (UV-Vis; Figure S5), 
7.  Preparation of IONP-OSi-CHO and DOX capture (UV-Vis; Figure S6),  
8. Preparation of diethyl (3-fluoro-4-formylphenyl)phosphonate,  
9. Preparation of IONP-3F4CPP and DOX capture (UV-Vis; Figure S7),  
10. SEM of IONP-commercial (Figure S8), IONP-3F4CPP (Figure S9) and IONP-3F4CPP-
HS (Figure S10),  
11. TEM of IONP-3F4CPP (Figure S11),  
12. Preparation of PEGylated IONP-3F4CPP,  
13. DOX capture profile from human serum (PEGylated Vs non-PEGylated; Figure S12),  
14. Preparation of IONP-BiFun,  
15. Synthesis of diethyl (2-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)ethyl)phosphonate,  
16. Preparation of IONP-3F4CPP-PEG-Cl 
17. ATR-IR spectra (Figure S13&14),  
18. CHN analysis (Table S2),  
19. DOX capture profile with error bars (Figure S15) and  
20. NMR Spectra (Figure S16-22) (PDF) 
21. References  
 
 
 
 
 
 
 
 
	 S3	
 
 
	 S1	
1. Imine formation in (D2O) 
Doxorubicin hydrochloride (DOX) (1 equiv, 9 µmol, 5.2 mg) was added to a solution of 
pyridoxal 5′-phosphate monohydrate (2.2 equiv, 19.6 µmol, 5.2 mg) in D2O (0.5 mL) and mixed 
until dissolved (» 5 min) and 1H NMR spectra were recorded.  
 
Figure S1 1H NMR spectra (H – aldehyde proton; H – imine proton) 
2. Preparation of IONP-VB6 
 
Scheme S1 Preparation of IONP-VB6 
 IONP (0.5g) was mixed with a solution of pyridoxal 5′-phosphate monohydrate (VB6) 
 (42 mg) in degassed deionized water (50 mL) and mechanically stirred at ambient temperature 
(IONP-VB6-RT), 50 °C (IONP-VB6-50C), 75 °C (IONP-VB6-75C) and 95 °C (IONP-VB6-95C) 
under a blanket of argon. The functionalized magnetic particles were collected at the bottom of the 
vial using rare earth magnets before decanting the solution. The magnetic particles were then 
washed with water, followed by drying at room temperature for 24 h under vacuum.  
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3. DOX capture from PBS using IONP-VB6 
The capture capacity was determined by mechanically shaking ~ 25 mg IONP-VB6 with a 
solution of doxorubicin (20 mL; 0.1 mg/mL) in phosphate buffer saline (PBS) at room temperature 
for 30 min. The solutions were analyzed by UV-Vis spectroscopy (representative UV-Vis; Figure 
S2).  
Table S1 Amount of DOX captured by IONP-B6 prepared at various conditions.  
Entry Amount of IONP used (mg) Material Amount of DOX (mg)/100mg IONP-VB6 
1 25.2 IONP-VB6-RT 3.84 
2 25.7 IONP-VB6-50C 4.61 
3 25.5 IONP-VB6-75C 3.84 
4 25 IONP-VB6-95 4.02 
a5 25.5 IONP-VB6-75C-72DH 3.96 
b6 25.1 IONP-VB6-75C-135DT-48DH 3.45 
c7 25.7 IONP-VB-50C-24h 3.72 
d8 25.6 IONP-VB6-50C-3XC 3.71 
 
a using IONP-VB6-75C dried at 120 °C for 72h. busing IONP-VB6-75C dried at 135 °C for 48h. 
c using IONP-VB6-50C dried at 120 °C for 24 hour. dused 2 times more VB6 for loading.  
 
  
Figure S2 Representative UV-Vis of DOX capture experiments using IONP-VB6-RT prepared 
at ambient temperature.  
 
 
 
-0.2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
340 390 440 490 540 590
DOX (0.1 mg/mL) in PBS
IONP-VB6 treated DOX
Vitamin B6
Wavelength (nm)
Ab
so
rb
an
ce
Ab
so
rb
an
ce
	(a
.u.
)	
	 S3	
 
4. Capture from human serum  
 
Figure S3 Emission spectra, excited at 483 nm and emission maximum observed at 595 nm  
 
5. Release of DOX aq. acid 
The IONP-VB6 used in the capture experiment was washed with water (3 X 5 mL). Then 
suspended in 5 mL water and a drop of acetic acid was added and warmed.  
 
 
Figure S4 DOX released in the presence of aq. acetic acid 
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6. Preparation of IONP-3,4-dihydroxybenzaldehyde and DOX capture  
 
 
Scheme S2 Preparation of IONP-3,4-dihydroxybenzaldehyde 
 A solution of 3,4-dihydroxybenzaldehyde (1 g) (DHBA) in THF (18 mL) was stirred with 
IONP (1 g) at room temperature for 1 hour and dried at 110 °C for 24 h under vacuum. The 
resulting solid was washed with THF (4 X 10 mL) and dried overnight under vacuum to get a free 
flowing solid (» 1g). The free flowing solid (12.1 mg) was used to capture DOX from PBS (0.1 
mg/mL; 5 mL) and the resulting solution was analyzed using UV-Vis spectroscopy. IONP-3,4-
dihydroxybenzaldehyde (100 mg) captures 2.8 mg of DOX. 
 
 
Figure S5 DOX capture experiment with IONP-34DHBA in PBS 
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7. Preparation of IONP-OSi-CHO and DOX capture  
 
 
Scheme S3 Synthesis of IONP-OSi-CHO 
 To a mixture of terephthalaldehyde (10 g) in THF (200 mL) and EtOH (200 mL; 200 proof) 
at 0 °C, NaBH4 (700 mg) was added portion wise and stirred overnight at room temperature. The 
reaction mixture was neutralized with 2M HCl and the volatiles were removed by rotary 
evaporation. The resulting residue was mixed with water and extracted in EtOAc, the combined 
organics was dried using anhy. MgSO4, filtered, and then dried under vacuum. The resulting mass 
was purified by column chromatography using EtOAc-Hexane gradient to get 4-
(hydroxymethyl)benzaldehyde as a colorless solid (8.1g, 80%). 1H NMR (500 MHz, Chloroform-
d) δ 10.07 (s, 1H), 7.94 (d, J = 8.2 Hz, 2H), 7.69 – 7.53 (m, 2H), 4.92 – 4.82 (s, 2H).1 4-
(hydroxymethyl)benzaldehyde (8 g) was mixed with 48% HBr (16 mL) and toluene (32 mL), and 
refluxed for 3 h. The resulting mixture was cooled to room temperature, and the volatiles removed 
via rotary evaporation, before being extracted into DCM. The combined layers were washed with 
sodium bicarbonate, water, brine, and then dried over MgSO4. The suspension was filtered and 
dried under vacuum to obtain 4-(bromomethyl)benzaldehyde, a pale yellow solid. 
Recrystallization from hexanes then afforded a white crystalline solid (10.8 g; 92%). 1H NMR 
(300 MHz, Chloroform-d) δ 10.02 (s, 1H), 7.92 – 7.81 (m, 2H), 7.62 – 7.49 (m, 2H), 4.52 (s, 2H). 
4-(bromomethyl)benzaldehyde (11 mmol; 2.18 g) was treated with 3-(2,8,9-trioxa-5-aza-1-
silabicyclo[3.3.3]undecan-1-yl)propane-1-thiol (10 mmol; 2.49 g) (prepared following literature 
procedure)2 in DMF under an argon atmosphere in the presence of K2CO3 for 24h. The reaction 
mixture was diluted with water and then extracted into DCM. The DCM layer was washed with 
water, brine, dried on anhy. MgSO4, and the volatiles removed using a rotary evaporator. The 
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resulting solid was recrystallized from toluene to get a pale-yellow solid (2.9 g, 80%). 1H NMR 
(300 MHz, Chloroform-d) δ 9.98 (s, 1H), 7.81 (d, J = 8.2 Hz, 2H), 7.48 (d, J = 8.1 Hz, 2H), 3.88 
– 3.52 (m, 8H), 2.80 (t, J = 5.8 Hz, 6H), 2.57 – 2.18 (m, 2H), 1.85 – 1.41 (m, 2H), 0.69 – 0.22 (m, 
2H). 13C NMR (101 MHz, Chloroform-d) δ 192.1, 146.9, 135.1, 130.0, 129.7, 57.9, 51.2, 36.0, 
35.3, 25.4, 16.1. HRMS (FAB+): Calculated for C17H24SSiNO4: 366.1195; found: 366.1180. IONP 
(1 g) was suspended in a solution of 2 (535 mg) in toluene and heated at 90 °C for 2h. The resulting 
IONP-Aldehyde was dried under vacuum at 120 °C for 24 hours, brought to room temperature, 
washed with toluene, water, and EtOH, and then dried under vacuum at room temperature for 24h 
to get a free flowing solid (933 mg). IONP-OSi-CHO (~10 mg; three independent experiments) 
were shaken at room temperature for 30 min in DOX solution (0.1 mg/mL, 10 mL) in PBS. The 
resulting solutions were analyzed by UV-Vis and the amount of DOX captured was calculated per 
~	100 mg of IONP-OSi-CHO to	be	approximately	3.8 ± 0.1mg. 
 
 
Figure S6 DOX capture experiment with IONP-OSi-CHO 
8. Preparation of diethyl (3-fluoro-4-formylphenyl)phosphonate (3) 
 The compound was prepared according to literature.3 To a mixture of potassium persulfate 
(2.7g; 100 mmol) and silver (I) oxide (679 mg; 2.5 mmol), a 1:1 (250 mL) mixture of water and 
acetonitrile was added. Subsequently, 2-fluorobenzaldehyde (6.2 g, 50 mmol) and diethyl 
phosphite (1.3 mL; 100 mmol) was added. This mixture was refluxed (bath temperature 100 °C) 
for 4 hours. The organics were then extracted into ethyl acetate, and dried on anhydrous MgSO4, 
before filteration and rotary evaporation to get a brown, gummy liquid. The crude was purified by 
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flash silica column chromatography using hexane/ethyl acetate gradient. The pure fractions were 
combined to get the desired product as a colorless liquid. 1H NMR (300 MHz, Chloroform-d) δ 
10.41 (d, J = 0.7 Hz, 1H), 8.07 – 7.87 (m, 1H), 7.78 – 7.57 (m, 2H), 4.33 – 3.96 (m, 4H), 1.35 (td, 
J = 7.1, 0.6 Hz, 6H). 31P NMR (121 MHz, Chloroform-d) δ 14.31 (d, J = 7.4 Hz). 19F NMR (282 
MHz, Chloroform-d) δ -120.72 – -121.02 (m). 
 
Scheme S4 Phosphorylation  
9. Preparation of IONP-3F4CPP and DOX capture  
 
Scheme S5 Synthesis of IONP-3F4CPP 
Iron oxide nanoparticles (5g; 30 nm) were suspended in a solution of diethyl (3-fluoro-4-
formylphenyl)phosphonate (505 mg) in toluene (50 mL) in a pressure tube and heated at 120 °C 
for 24 h with a mechanical rotation. The magnetic particles were held down with a rare earth 
magnet, before decanting the liquid. The solid was then washed with toluene (4 X 10 mL), 
followed by DCM (1 X 10 mL), before drying under vacuum for 24 h at 120 °C. The resulting 
solid was suspended in PBS (50 mL) at 45 °C for 2 h. The resulting mass was washed with PBS 
(4 X 30 mL), DI water (2 X 10 mL), and EtOH (2 X 10 mL), before drying under vacuum for 24h 
at RT to get free flowing IONP-3F4CPP (4.9 g). IONP-3F4CPP (» 10 mg) was shaken at room 
temperature for 30 min in DOX solution in PBS (0.05 mg/mL and 0.1 mg/mL). The resulting 
solution was analyzed by UV-Vis. Capture amount was calculated per (»100 mg) of the material 
from 0.05 mg/mL and 0.1 mg/mL solutions to be 2.42 ± 0.09 and 4.78 ± 0.06 mg, respectively. 
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Figure S7 DOX capture using IONP-3F4CPP from PBS 
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10. SEM and EDS 
 
Figure S8 IONP-Commercial 
 
 
Figure S9 IONP-3F4CPP 
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Figure S10 IONP-3F4CPP-HS-DOX (exposed to human serum with DOX) 
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11. TEM images of IONP-3F4CPP 
 
 
Figure S11 TEM images of IONP-3F4CPP 
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12. Preparation of PEGylated IONP-3F4CPP 
IONP-3F4CPP (350 mg) was shaken with an appropriate m-PEG (1 mmol in 10 mL 18 
MW water) for 2 h at room temperature. Free flowing particles were obtained after washing with 
water (3 x 5mL), EtOH (2 x 5 mL), and drying under vacuum for 24h.  
13. DOX capture from human serum  
DOX (0.6 – 0.7 mg) was dissolved in 400 µL 18 MW water and the resulting solution was 
diluted with appropriate amount of human serum to get the final concentration to be 0.05 mg/mL. 
DOX solution (10 mL; 0.05mg/mL) was mechanically shaken (motor speed 250) with IONP-
3F4CPP (»100 mg) in a vial (20 mL) at 37 °C for 30 min. Aliquots (200 µL) were withdrawn at 
prescheduled time intervals (1, 3, 5, 7, 10, 15, and 30 min). This was done by first removing the 
vial from the shaker and placing it on a rare-earth metal magnet for 20s to allow the magnetic 
particle to settle, before withdrawing the aliquot using a micropipette. The mixture was topped 
with human serum at every interval to maintain the total volume. The withdrawn samples were 
diluted with PBS (200 µL) in 2 mL glass vial and allowed to come to ambient temperature (» 30 
min), before being transferred into (3 X 100 µL) in a 96 wall opaque microplate reader. The plate 
was analyzed using a Flexstation 3. Fluorescence of the doxorubicin solution was determined by 
exciting at 483 nm and measuring the emission at 590 nm.  
 
Figure S12. DOX capture from human serum (0.05 mg/mL) at 37 °C using 100 mg of PEGylated 
functionalized IONP aldehyde.  
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14. Preparation of IONP-BiFun 
 
  
Scheme S7 Preparation of IONP-BiFun 
 To a mixture of diethyl (3-fluoro-4-formylphenyl)phosphonate (1.05 equiv, 2 mmol, 520 
mg), sodium 3-mercaptopropane-1-sulfonate(1 equiv; 89 mg), K2CO3 (1 equiv; 69 mg) was added 
in dry dimethyl formamide (DMF) under inert atmosphere and stirred at room temperature for 24h. 
The DMF was removed under vacuum and the resulting residue was dissolved ethanol and filtered. 
The resulting solid was dissolved in water and washed with DCM and water was evaporated and 
dried under vacuum to get a pale yellow solid (283 mg, 68%). 1H NMR (300 MHz, Deuterium 
Oxide) δ 10.25 (s, 1H), 8.02 (dd, J = 7.8, 4.7 Hz, 1H), 7.84 (dd, J = 14.4, 1.3 Hz, 1H), 7.76 (ddd, 
J = 12.9, 7.8, 1.3 Hz, 1H), 4.18 (dq, J = 8.3, 7.1 Hz, 4H), 3.22 (t, J = 7.2 Hz, 2H), 3.11 – 2.89 (m, 
2H), 2.20 – 1.98 (m, 2H), 1.31 (td, J = 7.1, 0.6 Hz, 6H). 13C NMR (101 MHz, D2O) δ 194.4, 141.4, 
141.2, 136.3, 133.5, 130.3, 128.0, 64.5, 49.6, 30.6, 23.3, 15.4. HRMS, calculated for C14H20O7S2P, 
395.0388; found, 395.0393. IONP (1g) was suspended in a solution of sodium 3-((5-
(diethoxyphosphoryl)-2-formylphenyl)thio)propane-1-sulfonate in toluene (10 mL), mechanically 
shaken at 120 °C for 24h in a sealed microwave vial (20 mL; Biotage). The resulting solid was 
washed with water (3 x 10 mL), EtOH (3 X 10 mL), and dried under vacuum at room temperature. 
The IONP-BiFun was resuspended in PBS 10 mL and heated at 45 °C for 2 h. The resulting mass 
was washed with PBS (4 X 5 mL), DI water (2 X 5 mL), EtOH (2 X 5 mL), and dried under 
vacuum for 24h at RT to get a free flowing solid (1g). Capture profile (Manuscript, Figure 3) was 
obtained following the procedure described above in three different experiments.  
 
 
 
 
 
 
 
F
P
OEtO OEt
O
S
P
OEtO OEt
O
SO3NaSO3NaHS
K2CO3, DMF, 24h P
OO
O
S
O
SO3Na
P
OO
O
S
O
SO3NaIONP, Toluene
120 oC
IONP
	 S14	
15. diethyl (2-(2-(2-(2-chloroethoxy)ethoxy)ethoxy)ethyl)phosphonate (4)  
 
Scheme S8 Phosphorylation  
Triethylphosphite (1.66 g; 10 mmol) was heated at with 1,14-dichloro-3,6,9,12-
tetraoxatetradecane (9.4 mL; 48 mmol) at 150 °C overnight and volatiles were removed under 
vacuum. The resulting mixture was purified by column chromatography using 6% MeOH/EtOAc 
to get a colorless liquid (1.57 g). 1H NMR (400 MHz, Chloroform-d) δ 4.09 (dqd, J = 7.8, 7.1, 4.2 
Hz, 4H), 3.82 – 3.54 (m, 14H), 2.13 (ddd, J = 18.7, 8.0, 7.1 Hz, 2H), 1.32 (t, J = 7.1 Hz, 6H). 31P 
NMR (162 MHz, Chloroform-d) δ 28.5. 13C NMR (101 MHz, Chloroform-d) δ 71.5, 70.8, 70.8, 
70.7, 70.3, 65.3, 61.8 (d, J = 6.4 Hz), 42.9, 27.1 (d, J = 139.1 Hz), 16.6 (d, J = 6.1 Hz). HRMS 
(FAB+): Calculated mass for C12H27ClO6P [M+H]: 333.1234; Found: 333.1225. 
16. Preparation of IONP-3F4CPP-PEG-Cl 
Iron oxide nanoparticles (1g; 30 nm) were suspended in a solution of diethyl (3-fluoro-4-
formylphenyl)phosphonate (100 mg) and 4 (11.2 mg) in toluene (10 mL) in a pressure tube and 
heated at 120 °C for 24 h with a mechanical rotation. The magnetic particles were held down with 
a rare earth magnet, before decanting the liquid. The solid was then washed with toluene (4 X 12 
mL), followed by DCM (1 X 2 mL), before drying under vacuum for 24 h at 120 °C. The resulting 
solid was suspended in PBS (10 mL) at 45 °C for 2 h. The resulting mass was washed with PBS 
(4 X 6 mL), DI water (2 X 2 mL), and EtOH (2 X 2 mL), before drying under vacuum for 24h at 
RT to get free flowing IONP-3F4CPP-PEG-C (965 mg). Capture profile (Manuscript, Figure 3) 
was obtained following the procedure described above in three different experiments. 
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17. ATR-IR  
 
Figure S13. Full ATR-IR spectra of IONP, IONP-3F4CPP-PEG-Cl, IONP-BiFun and IONP-
3F4CPP 
 
Figure S14. Overlaid ATR-IR spectra (1700-800 cm-1) of IONP, IONP-3F4CPP-PEG-Cl, IONP-
BiFun and IONP-3F4CPP  
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18. C, H, N analysis  
Table S2. Percentage of CHN (average of two samples) 
 
Sample ID % C % H % N 
IONP-Control  0.29 0.48 0.06 
IONP-3F4CPP 1.3 0.44 0.09 
IONP-3F4CPP-HS 3.17 0.68 0.72 
IONP-3F4CPP-mPEG-550-HS 3.16 0.69 0.73 
IONP-3F4CPP-mPEG-550 1.12 0.43 0.03 
IONP-3F4CPP-mPEG-550-DOX 3.38 0.68 0.83 
IONP-BiFun-HS 3.1 0.71 0.74 
IONP-BiFun 2.86 0.57 0.06 
IONP-BIFun-DOX 3.07 0.75 0.78 
IONP-3F4CPP-PEGCl 0.94 0.38 0.06 
IONP-3F4CPP-PEGCl-HS-DOX 3.65 0.81 0.92 
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19. DOX capture profile with error bars (Manuscript; Figure 3; Average of 3 runs) 
 
Figure S15 DOX capture profile of various functionalized IONP with error bars (average of 3 
runs) 
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20. NMR Spectra  
 
 
 
Figure S16 1H NMR (CDCl3) spectrum of 2 
 
 
 
 
Figure S17 13C NMR (CDCl3) spectrum of 2 
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1H NMR (CDCl3) 
 
Figure S18 1H NMR (CDCl3) spectrum of sodium 3-((5-(diethoxyphosphoryl)-2-
formylphenyl)thio)propane-1-sulfonate 
 
13C NMR (D2O) 
 
Figure S19 13C NMR (CDCl3) spectrum of sodium 3-((5-(diethoxyphosphoryl)-2-
formylphenyl)thio)propane-1-sulfonate 
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1H (CDCl3) 
 
Figure S20 1H (CDCl3) spectrum of (3-fluoro-4-formylphenyl)phosphonate 
 
 
Figure S21 13C NMR (CDCl3) spectrum of (3-fluoro-4-formylphenyl)phosphonate 
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31P NMR (CDCl3) 
 
Figure S22 31P NMR (CDCl3) spectrum of (3-fluoro-4-formylphenyl)phosphonate 
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